Meta Platforms is an advertising juggernaut with tremendous growth potential in the AI glasses market.
Micron Technology is a steal of a deal among AI stocks.
Mirum Pharmaceuticals may have multiple catalysts in 2026.
10 stocks we like better than Mirum Pharmaceuticals ›
The new year is not so new now. January is already almost halfway through. Before you know it, we’ll be looking ahead to 2027.
No one can slow down the hands of time. It is important to seize great opportunities as soon as possible. That’s why I believe the following three major growth stocks are excellent options to consider buying in the first half of 2026.
Image source: Getty Images.
I really like the growth prospects Meta Platforms(NASDAQ: META) she has with her Meta Ray-Ban Display glasses. They are the first artificial intelligence (AI) glasses with a private display in the lens and neural band pulse control. I consider Meta’s first mover advantage a huge advantage.
Is Meta CEO Mark Zuckerberg correct that glasses are “the ideal form factor for AI”? Yep. No other device can process everything a user sees and hears. It’s no surprise to me in the least that Meta is selling so many of its glasses in the US that it had to delay the global launch.
As excited as I am about Meta’s newest AI glasses, however, they aren’t the main reason to buy this stock right now. That honor belongs to the company’s massive user base that gives it pricing power with advertisers. A staggering 3.54 billion people used Meta apps on average every day in September 2025. This number reflected an 8% year-over-year increase. It is also almost 43% of the world’s population.
Those users don’t seem to be going. As long as that remains the case, Meta will generate billions of dollars in revenue and profits – and the company’s stock will likely perform well. AI glasses and Meta’s big bet on AI superintelligence (ASI) are just icing on the cake.
If you’re looking for a steal of a deal among AI stocks, however, you may want to buy shares of Micron Technology(name: mu). Its forward price to earnings ratio is 10.8. Micron’s price-to-earnings-to-growth (PEG) ratio, based on analysts’ five-year earnings growth projections, is a remarkably low 0.6.
Why is Micron stock so cheap? It is priced based on an outdated paradigm that views memory as merely a cyclical commodity. That perspective was correct until high bandwidth memory (HBM) became such a critical component of AI chips and the demand for AI chips exploded.
Micron disclosed in its fiscal 2026 first quarter earnings call that its entire projected HBM supply for the year is already fully allocated. The future looks bright too. Management estimates that the total addressable market for HBM will increase at a compound annual growth rate of approximately 40% through 2028.
The good news isn’t limited to HBM, either. Micron expects roughly 20% shipment growth for both DRAM (dynamic random access memory) and NAND (non-u) memory in 2026. CEO Sanjay Mehrotra believes “that aggregate industry supply will remain substantially short of demand for the foreseeable future.”
Amazing pharmaceuticals(NASDAQ: MIRM) is the oddball on the list. The drugmaker’s market cap of $4.5 billion is just a fraction of that of Meta and Micron. However, I predict that 2026 will be a big year for Mirum.
The company is coming off a tremendous performance in 2025. Mirum’s shares rose 91% last year. 2026 has also started well so far. Investors should keep a close eye on three key developments this year.
First, market momentum for Mirum Livmarli’s rare liver disease drug should continue. Sales increased 56% year over year to $92.2 million in the third quarter of 2025. I believe that Livmarli is on the right track to become Mirum’s first successful drug.
Second, Mirum expects to report results from its clinical study evaluating voloxibat in primary sclerosing cholangitis in the second quarter of 2026. If all goes well, the company may file for US regulatory approval in the second half of the year.
Third, Mirum’s pending acquisition of Bluejay Therapeutics could start paying off quickly. This agreement is expected to close in the first quarter of 2026. Bluejay plans to report phase 3 results for the chronic hepatitis delta virus (HDV) therapy brelovitug later in the year. I believe these results could provide a significant catalyst for Mirum stock.
Before buying stock in Mirum Pharmaceuticals, consider this:
the Motley Fool Stock Advisor a team of analysts has identified only what they believe they are 10 best stocks for investors to buy now… and Mirum Pharmaceuticals was not one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix I made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you would have $482,451!* Or when Nvidia I made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you would have $1,133,229!*
Now, it is worth noting Stock consultant total average income is 968% — a market-crushing outperformance compared to 197% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisorand join an investment community built by individual investors for individual investors.
See the 10 stocks »
*The Stock Advisor returns from January 13, 2026.
Keith Speights holds positions in Meta Platforms. The Motley Fool has positions in and recommends Meta Platforms and Mirum Pharmaceuticals. The Motley Fool has a disclosure policy.
The Top 3 Growth Stocks to Buy in the First Half of 2026 was originally published by The Motley Fool
